Page 2 - Retinal Prosthesis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: Second Sight Medical Products Inc (NASDAQ: EYES) shares have soared above 723% over the previous two trading sessions with the stock touching an intraday high of $14.83 on Monday. The shares registered a spike of nearly 103% as of Monday’s closing. What Happened: The California-based developer and marketer of implantable visual prosthetics said on Friday that the United States Food and Drug Administration had approved its Argus 2s Retinal Prosthesis System. The Argus 2s is used for the treatment of retinitis pigmentosa and is made up of glasses and a video processing unit to be used...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Second Sight Medical Receives FDA Approval for the Argus 2s Retinal Prosthesis System” Second Sight Medical (NASDAQ: EYES) Products surged just under 60% in premarket trading after the company announced the U.S. Food and Drug Administration has approved the Argus 2s Retinal Prosthesis System. The Company expects that the redesigned set of external hardware initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa, will be adapted to be the extern...